Literature DB >> 24145158

Association of comorbid generalized anxiety disorder and alcohol use disorder symptoms with health-related quality of life: results from the National Epidemiological Survey on Alcohol and Related Conditions.

Bernadette A Cullen1, Lareina N La Flair, Carla L Storr, Kerry M Green, Anika A H Alvanzo, Ramin Mojtabai, Lauren R Pacek, Rosa M Crum.   

Abstract

BACKGROUND: Although prior studies have documented the co-occurrence of generalized anxiety disorder (GAD) and alcohol use disorder (AUD) disorder, there is a paucity of research assessing the patterns of alcohol involvement among individuals with GAD symptoms. This study investigated subtypes, or classes, of comorbid AUD and GAD symptoms, and assessed the association of class membership with health-related quality of life.
METHODS: Using data from the Wave 1 of the National Epidemiologic Survey on Alcohol and Related Conditions, a latent class analysis was performed on the subset of individuals who were current drinkers and had reported ever experiencing a 6-month episode of feeling tense, nervous, or worried most of the time. We examined the association of these latent classes with physical and mental health-related quality of life measured by the Short Form-12, version 2.
RESULTS: Latent class analysis identified a 5-class model of AUD and GAD symptoms. A significant graded relationship was observed between the ordered classes and severity of impairment on the mental health scale of the Short Form-12, version 2, but no significant relationship was found with the physical health scale.
CONCLUSIONS: Mental, but not physical, health-related quality of life in this population is associated with both the number and pattern of comorbid GAD and AUD symptoms.

Entities:  

Mesh:

Year:  2013        PMID: 24145158      PMCID: PMC3839307          DOI: 10.1097/ADM.0b013e31829faa1c

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  19 in total

1.  Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Deborah S Hasin; Frederick S Stinson; Deborah A Dawson; W June Ruan; Risë B Goldstein; Sharon M Smith; Tulshi D Saha; Boji Huang
Journal:  Psychol Med       Date:  2005-10-05       Impact factor: 7.723

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization.

Authors:  R C Kessler; C B Nelson; K A McGonagle; M J Edlund; R G Frank; P J Leaf
Journal:  Am J Orthopsychiatry       Date:  1996-01

4.  Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Kevin P Conway; Wilson Compton; Frederick S Stinson; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

Review 5.  The epidemiology of generalized anxiety disorder.

Authors:  R C Kessler; M B Keller; H U Wittchen
Journal:  Psychiatr Clin North Am       Date:  2001-03

6.  Intimate partner violence and patterns of alcohol abuse and dependence criteria among women: a latent class analysis.

Authors:  Lareina N La Flair; Catherine P Bradshaw; Carla L Storr; Kerry M Green; Anika A H Alvanzo; Rosa M Crum
Journal:  J Stud Alcohol Drugs       Date:  2012-05       Impact factor: 2.582

7.  The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999.

Authors:  Ron Z Goetzel; Kevin Hawkins; Ronald J Ozminkowski; Shaohung Wang
Journal:  J Occup Environ Med       Date:  2003-01       Impact factor: 2.162

8.  Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment.

Authors:  Joshua P Smith; Sarah W Book
Journal:  Addict Behav       Date:  2009-08-07       Impact factor: 3.913

9.  The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample.

Authors:  Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

10.  Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Deborah S Hasin; Frederick S Stinson; Elizabeth Ogburn; Bridget F Grant
Journal:  Arch Gen Psychiatry       Date:  2007-07
View more
  3 in total

1.  β-Endorphin neuronal transplantation into the hypothalamus alters anxiety-like behaviors in prenatal alcohol-exposed rats and alcohol-non-preferring and alcohol-preferring rats.

Authors:  Ryan W Logan; Olivia Wynne; George Maglakelidze; Changqing Zhang; Stephanie O'Connell; Nadka I Boyadjieva; Dipak K Sarkar
Journal:  Alcohol Clin Exp Res       Date:  2015-01       Impact factor: 3.455

2.  Current tobacco use, nicotine dependence, and transitions across stages of alcohol involvement: A latent transition analysis approach.

Authors:  Lauren R Pacek; Beth A Reboussin; Kerry M Green; Lareina N LaFlair; Carla L Storr; Anika A H Alvanzo; Ramin Mojtabai; Bernadette Cullen; Andrea S Young; Kayla Tormohen; Kira Riehm; Rosa M Crum
Journal:  Int J Methods Psychiatr Res       Date:  2019-05-29       Impact factor: 4.035

Review 3.  Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research.

Authors:  M Taylor Wilmer; Kelley Anderson; Monique Reynolds
Journal:  Curr Psychiatry Rep       Date:  2021-10-06       Impact factor: 5.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.